SCHEMBL7708356

SCHEMBL7708356

CC1Oc2ccc(C(Cc3ccc(F)cc3)NC(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
ALDH1A1 P00352 8/20 0.39
HTT P42858 5/20 0.39
NPSR1 Q6W5P4 5/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 3/20 0.39
TP53 P04637 2/20 0.39
JAK2 O60674 2/20 0.39
MAPK1 P28482 1/20 0.39
ATM Q13315 1/20 0.39
TSHR P16473 6/20 0.39
LMNA P02545 5/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
PKM P14618 3/20 0.36
MAPT P10636 1/20 0.36
AGTR1 P30556 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711369 0.93 ALDH1A1 (0.37) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7708193 0.92 ALDH1A1 (0.38) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7704969 0.91 ALDH1A1 (0.36) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7704912 0.91 ALDH1A1 (0.45) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7711250 0.91 ALDH1A1 (0.46) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7704948 0.90 SMN1; SMN2 (0.40) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7711330 0.90 CTSS (0.36) CTSSCTSKALDH1A1HTTNPSR1
SCHEMBL7713438 0.89 PTPRB (0.38) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7710751 0.89 CA2 (0.41) ALDH1A1HTTNPSR1HPGDHSD17B10
SCHEMBL7708354 0.88 PPARG (0.39) ALDH1A1HTTNPSR1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed